Novel Antiplatelet Agents in Cardiovascular Disease

Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of Cardiovascular Disease. Aspirin, adenosine diphosphate P2Y₁₂ receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the Thrombin receptor blocker vorapaxar are effective antiplatelet agents but significantly increase the risk of bleeding. Moreover, atherothrombotic events still impair the prognosis of many patients with Cardiovascular Disease despite established antiplatelet therapy. Over the last years, advances in the understanding of thrombus formation and hemostasis led to the discovery of various new receptors and signaling pathways of platelet activation. As a consequence, many new antiplatelet agents with high antithrombotic efficacy and supposedly only moderate effects on regular hemostasis have been developed and yielded promising results in preclinical and early clinical studies. Although their long journey from animal studies to randomized clinical trials and finally administration in daily clinical routine has just begun, some of the new agents may in the future become meaningful additions to the pharmacological armamentarium in Cardiovascular Disease.

antiplatelet therapy; cardiovascular disease; targets.